SG11201805957QA - Composition for inhibiting endotoxin entry into blood - Google Patents

Composition for inhibiting endotoxin entry into blood

Info

Publication number
SG11201805957QA
SG11201805957QA SG11201805957QA SG11201805957QA SG11201805957QA SG 11201805957Q A SG11201805957Q A SG 11201805957QA SG 11201805957Q A SG11201805957Q A SG 11201805957QA SG 11201805957Q A SG11201805957Q A SG 11201805957QA SG 11201805957Q A SG11201805957Q A SG 11201805957QA
Authority
SG
Singapore
Prior art keywords
entry
blood
composition
inhibiting endotoxin
endotoxin
Prior art date
Application number
SG11201805957QA
Inventor
Hisae Kume
Keiko Okazaki
Kinya Ashida
Original Assignee
Meiji Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Co Ltd filed Critical Meiji Co Ltd
Publication of SG11201805957QA publication Critical patent/SG11201805957QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SG11201805957QA 2016-01-22 2017-01-20 Composition for inhibiting endotoxin entry into blood SG11201805957QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016010840 2016-01-22
PCT/JP2017/001856 WO2017126645A1 (en) 2016-01-22 2017-01-20 Composition for inhibiting migration of endotoxin into blood

Publications (1)

Publication Number Publication Date
SG11201805957QA true SG11201805957QA (en) 2018-08-30

Family

ID=59362471

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805957QA SG11201805957QA (en) 2016-01-22 2017-01-20 Composition for inhibiting endotoxin entry into blood

Country Status (6)

Country Link
JP (1) JP7383874B2 (en)
CN (1) CN108472331A (en)
HK (1) HK1255895A1 (en)
SG (1) SG11201805957QA (en)
TW (1) TW201735942A (en)
WO (1) WO2017126645A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023106078A1 (en) * 2021-12-10 2023-06-15 森永乳業株式会社 Nutritional composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008033A1 (en) * 1990-03-14 1991-09-19 Nitsche Dietrich USE OF LACTOFERRINE TO CONTROL THE TOXIC EFFECT OF ENDOTOXIN
JPH07278013A (en) * 1994-03-31 1995-10-24 Snow Brand Milk Prod Co Ltd Neutralizing agent for endotoxin
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
JP4672163B2 (en) 2000-03-24 2011-04-20 明治乳業株式会社 A composition for inducing specific antibody production against lipid A of gram-negative bacteria.
TWI317636B (en) 2002-11-22 2009-12-01 Meiji Dairies Corp Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress
TWI612902B (en) * 2009-11-30 2018-02-01 Meiji Co Ltd Use of a composition for manufacturing an improved intestinal functional composition and preparation method thereof
JP6234227B2 (en) 2011-11-30 2017-11-22 株式会社明治 Nutritional composition for improving intestinal flora
JP5501416B2 (en) 2012-08-08 2014-05-21 本田技研工業株式会社 Transmission cooling duct for saddle riding type vehicles

Also Published As

Publication number Publication date
JPWO2017126645A1 (en) 2018-11-08
WO2017126645A1 (en) 2017-07-27
TW201735942A (en) 2017-10-16
HK1255895A1 (en) 2019-08-30
JP7383874B2 (en) 2023-11-21
CN108472331A (en) 2018-08-31

Similar Documents

Publication Publication Date Title
SG11201705093UA (en) Composition for treating il-6-related diseases
GB201512030D0 (en) Composition
GB201505527D0 (en) Composition
GB201521507D0 (en) Composition
GB201506827D0 (en) Composition
GB201515640D0 (en) Composition
GB201506829D0 (en) Composition
GB201506830D0 (en) Composition
GB201506825D0 (en) Composition
GB201517546D0 (en) Composition
GB201506828D0 (en) Composition
GB201518348D0 (en) Composition
GB201514585D0 (en) Composition
PT3106160T (en) Combination composition comprising huperzine
GB201511697D0 (en) Composition
GB201509044D0 (en) Composition
GB201505520D0 (en) Composition
GB201504665D0 (en) Composition
GB201504307D0 (en) Composition
ZA201608407B (en) Stain treatment compositions
GB201519327D0 (en) Composition
GB201515639D0 (en) Composition
SG11201805957QA (en) Composition for inhibiting endotoxin entry into blood
GB201508722D0 (en) Composition
GB201506826D0 (en) Composition